Protalix BioTherapeutics, Inc.
PLX- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001006281
No open-market purchases or sales by Protalix BioTherapeutics, Inc. insiders were filed in the last 90 days; 101 institutions reported holding it in 13F filings for Q2 2026, worth $33.7M in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding Protalix BioTherapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 33 | 35 | +2 |
| Shares | 4.32M | 4.42M | +98.5K (+2.3%) |
| Value | $8.24M | $5.91M | −$2.33M (−28.3%) |
New holders (7)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Gsa Capital Partners LLP | 254,871 | $339.0K | 0.03% |
| IHT Wealth Management, LLC | 33,200 | $44.0K | 0.00% |
| Two Sigma Advisers, LP | 14,200 | $19.0K | 0.00% |
| JPMorgan Chase & Co | 5,847 | $8.00K | 0.00% |
| Psagot Value Holdings Ltd. / (Israel) | 6,000 | $8.00K | 0.00% |
| Migdal Insurance & Financial Holdings Ltd. | 4,000 | $5.00K | 0.00% |
| Harbour Investments, Inc. | 3,000 | $4.00K | 0.00% |
Sold out (5)
Institutions that held Protalix BioTherapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Renaissance Technologies LLC | 30,075 | $57.0K |
| Tower Research Capital LLC (TRC) | 4,658 | $9.00K |
| Red Door Wealth Management, LLC | 2,000 | $3.00K |
| Deutsche Bank AG | 873 | $2.00K |
| Gemmer Asset Management LLC | 800 | $2.00K |